Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: A new strategy?  by Kelley, Robin K. & Yao, Francis
EditorialSalvage liver transplantation for recurrent hepatocellular
carcinoma after radiofrequency ablation: A new strategy?
Robin K. Kelley1,, Francis Yao2,⇑
1Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), United States;
2Division of Gastroenterology, University of California, San Francisco (UCSF), United States
See Article, pages 160–166In this issue of the Journal, Dr. Nkontchou et al. describe the
recurrence and survival outcomes of a retrospective cohort of
67 patients diagnosed with hepatocellular carcinoma (HCC)
within the Milan criteria between 2000 and 2007, who were trea-
ted at a single center in France with percutaneous radiofrequency
ablation (RFA), followed by close surveillance and salvage trans-
plant for liver failure or recurrence [1]. Among the 64 patients
who achieved complete response to RFA, 38 (59.4%) experienced
recurrence within 5 years. Twenty-one patients with recurrence
were treated by liver transplantation, 14 were ineligible due to
recurrence outside of the Milan Criteria, and 3 declined trans-
plant and were treated with repeat RFA. Three additional patients
from the original cohort required transplantation for hepatic
decompensation without recurrence. The 5-year overall and
recurrence-free survival rates were 74% and 69%, respectively.
The authors conclude that RFA as a ﬁrst-line strategy reserving
liver transplant as a salvage option achieves ‘‘survival ﬁgures that
are as least as good as ﬁrst line liver transplantation,’’ in patients
with HCC within the Milan Criteria and Child Pugh A cirrhosis,
and that this two-step strategy may help to conserve the scarce
resource of liver allografts.
Particularly when facing widespread organ shortages, there is
great need for studies such as Nkontchou et al. which seek to
identify those patients who will experience equivalent outcomes
from loco-regional therapies as from transplantation, thereby
safeguarding graft livers for patients most likely to beneﬁt,
including patients with other indications for transplantation for
whom similar alternative treatment options may not be available
[2,3]. It is clear that, although the Milan Criteria remain a world-
wide standard for identifying appropriate candidates for liver
transplantation, there are patients, whose tumors meet theseJournal of Hepatology 20
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Sates. Tel.: +1 415 353 9888; fax: +1 415 353 7984.radiographic criteria, who may have excellent survival outcomes
from loco-regional therapy alone, while others with similar base-
line imaging ﬁndings develop distant metastatic disease despite
transplantation [4–8].
In non-randomized, retrospective cohort analyses, however,
careful examination of patient selection criteria is imperative to
guide interpretation of results. In Nkontchou et al., 22 out of the
67 patients (33%) were classiﬁed as Barcelona Clinic Liver Cancer
(BCLC) Stage 0 (very early stage disease) at baseline, and the
remainder had BCLC1 disease [1]. In the United States, patients
with BCLC0 and BCLC1 HCC and evidence of minimal or no portal
hypertension are generally recommended to undergo liver resec-
tion rather than transplantation given similar published survival
rates in this subpopulation along with the need to preserve organ
resources [3,4,9–11]. The authors state thatmost of the patients in
this study were selected for RFA due to tumor anatomic location
and/or portal hypertension as contraindications to liver resection,
though the proportion of patients with adequate hepatic reserve
for liver resection is not provided, and it is unclear how candidacy
for resection was adjudicated in this cohort. It is noteworthy that
2 out of the 3 patients, who failed to demonstrate a complete
response to ﬁrst-line RFA, were treated thereafter with resection.
Conﬂicting data regarding the efﬁcacy of resection versus RFA for
BCLC early and very early stage HCC confound interpretation of
the ﬁndings in this study, noting in particular a body of evidence
suggesting that RFA is associated with a higher local recurrence
rate than resection as recently reviewed by Kudo [5]. Nkontchou
et al. deﬁne ‘‘local recurrence’’ as recurrent tumor at the previ-
ously treated site(s), while ‘‘distant recurrence’’ is deﬁned as the
emergence of one or several tumors not adjacent to an ablation
site. Among the 38 patients with recurrence post complete
response to ﬁrst-line RFA in this cohort, 2 patients had local recur-
rence, 33 patients had distant recurrence, and 3 patients had both.
The anatomic proximity required to be considered adjacent is not
deﬁned. It is also not stated whether any of the patients with
recurrence were candidates for resection. Cumulatively, these
points raise the following important question: Would a propor-
tion of the patients studied by Nkontchou et al. have been spared
from intrahepatic recurrence requiring salvage transplantation
had they been treated with ﬁrst-line resection? This question can-
not be rigorously answered by non-randomized data, however,12 vol. 56 j 14–16
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and any inferences require careful identiﬁcation of appropriate
historical controls.
A closely-related question emerges when examining the med-
ian time to recurrence in this cohort of patients treated with ﬁrst-
line RFA with curative intent. Although the authors report that all
but 3 of the 67 patients had a complete response to RFA as
deﬁned by the absence of enhancing tissue at the tumor site(s)
on imaging one month later, the remaining recurrences in this
study occurred quite early, with median time to recurrence of
1.16 years (95% CI: 0.71; 2.58). For patients with recurrence, the
median time to transplant was 1.38 years (95% CI: 0.58; 1.92)
from the time of the initial RFA with a median waiting time of
5 months. The short interval between median times to recurrence
and transplant suggests that the distribution of recurrences was
skewed toward an even earlier mean, though this ﬁgure is not
provided. Considering the rapidity of recurrences in this study
along with the data cited above suggesting higher local recur-
rence rates with RFA by comparison to resection, it is possible
that many of the recurrences in this study actually represent pre-
existing lesions that were occult on baseline and post-RFA imag-
ing rather than de novo secondary lesions. It is unclear whether
imaging practices were symmetric across patients; the authors
state that ‘‘ultrasound, triphasic computerized tomography, or
magnetic resonance imaging’’ was performed one month after
RFA then every three months, but they do not specify whether
all patients were mandated to undergo at least one of the multi-
phase contrast-enhanced options at each timepoint. Incomplete
initial RFA could also explain the rapid time to recurrence but is
not supported by the explant histology ﬁndings which showed
complete necrosis at the site of RFA in most patients, though
the histology and location of recurrent lesions is not described.
Based upon this rapid time to recurrence, suggesting a high like-
lihood of residual disease post RFA, it may be more accurate to
consider RFA as a bridge to transplant for the majority of patients
in this cohort, rather than as a deﬁnitive therapy with transplant
as a salvage measure. The rapid time to transplant in this series
also calls into question whether the salvage strategy in this study
can be generalized to sites with longer waiting list times.
At ﬁrst glance, the 5-year overall and recurrence-free survival
rates in this cohort appear promising. Nkontchou et al. compare
the survival outcomes in this study to historical control data from
patients treated with ‘‘ﬁrst-line’’ transplantation and conclude
that ﬁrst-line RFA in this patient population is associated with
similar if not better results. Looking more closely, however, it is
not surprising that the survival of patients in Nkontchou et al.,
all of whom were Child Pugh A with early stage disease, would
compare favorably to the heterogeneous, often pre-treated popu-
lations in HCC transplantation studies, particularly if intent-to-
treat analyses are employed which are heavily inﬂuenced by
drop-out. The majority of studies of liver transplantation include
patients with higher Model for End-Stage Liver Disease (MELD)
scores, more advanced tumors, and prior loco-regional therapies,
and many transplantation algorithms exclude early-stage
patients eligible for resection [8,11–13]. In a retrospective cohort
study of patients treated with liver transplantation for HCC
before and after the adoption of MELD allocation system, 3595
patients with tumorsP2 cm underwent transplantation with
MELD exception points between 2002 and 2007 in the United
States [8]. Subset analysis according to tumor size and number
of nodules demonstrated 4-year overall survival rates ranging
from 69.1% to 79.4%, with the highest rate for patients with soli-Journal of Hepatology 20tary tumors less than 2 cm in size. The majority (65.1%) of the
overall population had received prior treatment for HCC, and
MELD scores were widely distributed. It is difﬁcult and perhaps
premature to draw any ﬁrm conclusions regarding the outcomes
of patients in the Nkontchou et al. cohort compared to outcomes
in liver transplantation studies due to this heterogeneity.
In addition to a high degree of clinical heterogeneity, however,
HCC is a tumor with exceptional biologic heterogeneity that is
thought to arise from longstanding inﬂammation and hepatocyte
regeneration from underlying liver injury [14]. Gene expression
proﬁling in HCC suggests there may be common molecular and
genetic subclasses in HCC, including several distinct subclasses
with greater genetic instability, high grade histology, and poor
clinical outcome [14–18]. Certain clinical features, such as high
AFP and hepatitis B virus infection, are often associated with
the most aggressive subclasses [14]. It is probable that intrinsic
tumor biology, for which radiographic features are merely a
crude surrogate marker, is a much stronger determinant of
patient outcome than the type, technique, or timing of liver-
directed interventions or transplantation. In small, non-random-
ized cohorts, the chance proportion of patients with aggressive
molecular and genetic subtypes of tumor has great potential to
drive results and confound interpretation.
Although not yet a standard of care in risk assessment and
treatment decision-making in HCC, molecular and genetic studies
of HCC tumors at diagnosis and recurrence have great investiga-
tional promise to answer important clinical questions, such as
whether the recurrences represent clonal intrahepatic metastases
from a single primary tumor as opposed to de novo secondary
tumors, and which patients are at highest risk of metastatic
recurrence and unlikely to beneﬁt from loco-regional strategies.
Due to the validation of radiographic diagnoses without biopsy
in HCC as well as the concerns of tumor seeding and bleeding
in potential transplant candidates, there is a paucity of tissue
available for research purposes in HCC, a deﬁciency which may
contribute to the very dismal treatment options for patients with
advanced HCC by comparison to nearly all other cancer types.
Studies such as this offer an invaluable opportunity to obtain
paired biopsy material for molecular and genetic analyses with-
out conferring undue risk to patients who will already be under-
going RFA and, in many cases, subsequent transplantation.
Nkontchou et al. hypothesize that a two-step strategy pro-
vides a necessary ‘‘test of time’’ to identify those patients with
aggressive tumor biology most likely to recur post transplanta-
tion. This hypothesis is in keeping with results from our experi-
ence at the University of California, San Francisco (UCSF) using
a downsizing approach prior to transplantation in patients with
HCC tumors exceeding the Milan Criteria [19,20]. In a cohort of
61 patients treated with RFA and/or chemoembolization to
downsize tumors, approximately 30% of patients experienced
radiographic progression during the waiting period and were
excluded. The remaining patients underwent transplantation a
median of 8.2 months after the initial downsizing procedure.
Outcomes were excellent with intention-to-treat survival of
69.3% at 4 years [20]. The UCSF experience along with other stud-
ies suggest that an ‘‘Ablate and Wait’’ strategy will facilitate iden-
tiﬁcation of those patients with unfavorable tumor biology who
demonstrate progression despite downsizing techniques and
who are, unfortunately, unlikely to beneﬁt from transplantation.
In summary, Nkontchou et al. have described a cohort of
patients with preserved hepatic function and HCC within the12 vol. 56 j 14–16 15
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Milan Criteria treated with ﬁrst-line RFA and salvage transplant,
with the important goal of improving the allocation of liver allo-
grafts to those patients most likely to beneﬁt. Although the sur-
vival outcomes in this cohort appear promising, the results
cannot be generalized to the broader population of patients with
HCC within Milan Criteria due to the highly selected, early-stage
patient population and the short waiting list times for patients
with recurrence. Another major limitation of this study is the lack
of clear deﬁnition of resectability, noting that the current litera-
ture suggests higher recurrence rates post RFA by comparison
to liver resection. The early median time to recurrence in this
study also raises the possibility of incomplete response to RFA
versus occult residual disease in the majority of patients with
recurrence, rather than de novo tumors. Although the authors
conclude that this treatment strategy is associated with survival
outcomes equivalent to if not better than ﬁrst-line transplanta-
tion, the comparison is confounded by great clinical and biologic
heterogeneity among HCC patients and their tumors. Impor-
tantly, this study corroborates other recent work suggesting that
a two-step approach with a mandatory waiting period prior to
transplantation may permit identiﬁcation of those patients with
biologically-unfavorable disease most likely to recur post trans-
plant, thereby sparing these patients from a high risk procedure
without beneﬁt while conserving the scarce resource of liver allo-
grafts. A better understanding of tumor biology is critical to reﬁne
our assessment of which patients are most and least likely to
beneﬁt from loco-regional therapies and transplant, as well as
to identify novel therapeutic targets in this complex and grim
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